In this microsimulation study, Sanjay Basu and colleagues assess the potential impact of newer diabetes medications, such asGLP-1 receptor agonists and SGLT2 inhibitors, on insulin dosage and health outcomes in low- and middle-income countries. The gene discussed is INS; the disease is diabetes mellitus.